Ross Abrams to Fluorouracil
This is a "connection" page, showing publications Ross Abrams has written about Fluorouracil.
Connection Strength
1.812
-
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2012 Feb 01; 82(2):809-16.
Score: 0.373
-
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008 Jul 20; 26(21):3503-10.
Score: 0.313
-
Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. Arch Surg. 2007 Mar; 142(3):285-8.
Score: 0.284
-
Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet. 2001 Nov 10; 358(9293):1565-6.
Score: 0.197
-
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):317-26.
Score: 0.108
-
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008 Mar 05; 299(9):1019-26.
Score: 0.076
-
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys. 2007 May 01; 68(1):178-82.
Score: 0.071
-
Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985? Int J Radiat Oncol Biol Phys. 2003; 56(4 Suppl):3-9.
Score: 0.053
-
Adjuvant therapy for pancreatic adenocarcinoma. J Gastrointest Surg. 2001 Jan-Feb; 5(1):6-7.
Score: 0.046
-
Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys. 1999 Jul 15; 44(5):1039-46.
Score: 0.042
-
Adjuvant therapy for pancreatic cancer: back to the future. Int J Radiat Oncol Biol Phys. 1998 Aug 01; 42(1):59-63.
Score: 0.039
-
Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center. Cancer J Sci Am. 1998 May-Jun; 4(3):178-84.
Score: 0.039
-
RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):554-60.
Score: 0.032
-
Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg. 1993 Feb; 217(2):149-54.
Score: 0.027
-
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011 May; 18(5):1319-26.
Score: 0.023
-
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol. 2011 Feb; 22(2):348-54.
Score: 0.022
-
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009 Jan; 136(1):187-95.
Score: 0.020
-
A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):965-6.
Score: 0.015
-
Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):19-27.
Score: 0.012
-
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys. 2000 Nov 01; 48(4):1089-96.
Score: 0.011
-
Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy. Int J Radiat Oncol Biol Phys. 1996 Apr 01; 35(1):143-50.
Score: 0.008